Flutomidate was studied as a hypnotic agent. Information about the current use of this agent is not available.

Setoperone is and antagonist of the brain serotonin 5-HT2 receptor and particular the 5-HT2A isoform. Setoperone is radiolabeled with the radioisotope fluorine-18 and is used in positron emission tomography (PET) in neuroimaging for the study neuropsychiatric disorders, such as schizophrenia and depression.

Etoloxamine is an antihistamine.

Etolorex is an anorectic agent.

Delanterone is an antiandrogen steroid, developed by the Dutch company Gist-Brocades N.V. for the treatment of various dermatological disorders, including hirsutism, acne, seborrhea, alopecia androgenetica, and baldness. The compound is claimed to show topical anti-androgenic activity with very weak systemic anti-androgenic activity, a lack of progesterone, anti-gonadotrophin and corticosteroid-like activity and very low toxicity.

Mespirenone (ZK 94679, 15β,16β-methylene-spironolactone) is a steroid aldosterone antagonist. In addition, it is a quite specific inhibitor of adrenocortical mineralocorticoid synthesis. In rodents mespirenone effectively prevents aldosterone-induced hypertension. It exerts natriuretic efficacy. Although it reached phase II clinical trials, it was discontinued in 1989.

Vindeburnol, a derivative of the plant alkaloid vincamine that that bears neuroprotective properties. Animal model for Alzheimer's disease has shown that vindeburnol reduced neuroinflammation and amyloid burden. In addition, the treatment with this drug can be of benefit in multiple sclerosis patients.

Lorpiprazole (brand name Normarex) is a marketed anxiolytic drug of the phenylpiperazine group. It has been described as a serotonin antagonist and reuptake inhibitor (SARI) in the same group as trazodone, nefazodone, and etoperidone.

Droloxifene, a derivative of the triphenylethylene drug tamoxifen, is a novel selective estrogen receptor modulator (SERM). Droloxifene also exhibits more rapid pharmacokinetics, reaching peak concentrations and being eliminated much more rapidly than tamoxifen. Its higher affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of cell growth and division in estrogen receptor-positive cell lines, and lower toxicity give it theoretical advantages over tamoxifen in the treatment of human breast cancer. Short-term toxicity was generally mild, and similar to that seen with other antiestrogens. Droloxifene appears active and tolerable. It may have a particular role in situations in which rapid pharmacokinetics, or an increased antiestrogenic to estrogenic ratio, are required. Droloxifene may also be a potentially useful agent for the treatment of postmenopausal osteoporosis because it can prevent estrogen deficiency-induced bone loss without causing uterine hypertrophy. Droloxifene may have an effect on bone and breast tissue because it induces apoptosis. Droloxifene has an anti-implantation effect in rats, and the effect appears to be not completely due to its anti-estrogenic activity.

Butaclamol is an antipsychotic drug, which was studied for the treatment of schizophrenia. This drug has never marketed and now is used in research, because of its action as a dopamine receptor-blocking agent. Butaclamol consists of the two forms: (-)-butaclamol, an inactive drug and (+)-butaclamol, a potent neuroleptic drug.